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Abstract Transplantation of cryopreserved ovarian tissue has been shown to induce pregnancies and puberty successfully. There-
fore, using cryopreserved ovarian tissue to postpone menopause (tissue hormone therapy [THT]) seems to be an interesting option
to avoid conventional menopause hormone therapy (MHT). Pregnancy induction and replacing MHT by THT, however, are com-
pletely different topics as different requirements need to be met. First, MHT requires long-lasting and continuous hormone produc-
tion. It still needs to be proven if the transplanted tissue is active for at least 5 years with a continuous follicle growth to avoid phases
with low oestrogen production, which would otherwise cause menopausal symptoms and could reduce the postulated beneﬁt for women’s
health. Second, the advantage of a physiological hormone production over a non-physiological MHT is still hypothetical. Third, women
who have undergone hysterectomies who do not need progesterone for endometrial protection would only require oestrogens, im-
posing more health beneﬁts (cardiovascular system, mammary gland) than oestrogen and progesterone production or replacement.
Therefore, transplanting ovarian tissue exclusively to postpone menopause is endocrinologically doubtful and should only be carried
out within clinical trials.
© 2015 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.
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Introduction
The ﬁrst live birth to take place after ovarian tissue trans-
plantation was in 2004 (Donnez et al., 2004). Since then,
cryopreservation of ovarian tissue has become a widely used
fertility-preservation technique for women with maligancies
about to undergo cytotoxic therapies. Currently, the deliv-
ery rate per transplantation is about 24% (Liebenthron et al.,
2015). Ovarian tissue activity remains in up to 70% of cases
1 year after transplantation (Liebenthron et al., 2015);
however, the delivery rate per transplantation is expected
to further increase. Also, as only about one-third to one-
half of the cryopreserved tissue is used per transplantation,
re-transplantations will be possible in most cases.
Ovarian tissue has also been used to induce puberty in chil-
dren with ovarian failure owing to previous cytotoxic therapy
(Ernst et al., 2013), proving that tissue hormone therapy (THT)
may induce a sufﬁcient rise in serum oestrogen levels, and
may also replace exogenous hormone replacement therapy
in certain cases.
Therefore, a consequential next step would be to use
cryopreserved ovarian tissue to postpone menopause instead
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of applying a conventional menopausal hormone therapy
(MHT). As this option has already been suggested by repro-
ductive physicians and biologists without adequately address-
ing the endocrinological aspects (Andersen and Kristensen,
2015), our discussion will focus on the latter. To make a better
comparison of both treatment options, we have coined the
expression ‘tissue hormone therapy’ (THT) as a counterpart
to the commonly known MHT.
Endocrinological aspects
The Women’s Health Initiative is a prospective, random-
ized, placebo-controlled trial, aimed to assess the risk and
preventive factors associated with the most common causes
of death, disability and reduced quality of life in postmeno-
pausal women (Manson et al., 2013). Subsequent subanalyses
and randomized-controlled trials have provided a better
picture of the risk–beneﬁt proﬁle of MHT. In the Women’s
Health Initiative (Manson et al., 2013), postmenopausal women
with an intact uterus were treated with either conjugated
equine oestrogens (CEE) (0.625 mg/d) combined with
medroxyprogesterone acetate (MPA) (2.5 mg/d) or placebo,
whereas women who had undergone hysterectomies re-
ceived either CEE (0.625 mg/d) or placebo, respectively.
During the CEE plus MPA intervention phase, risk of stroke,
pulmonary embolism, invasive breast cancer and dementia
(in women aged ≥65 years) was increased, whereas beneﬁts
included decreased vasomotor symptoms, hip fractures and
diabetes, respectively (Manson et al., 2013). For combined
MHT, however, breast cancer risk may differ for various pro-
gestogens, as the breast proﬁle has been reported to be ‘safer’
for oestrogens combined with micronized (natural) proges-
terone. Risks and beneﬁts were more balanced during the CEE
alone intervention. Importantly, breast cancer risk was non-
signiﬁcantly reduced during the intervention phase, becom-
ing signiﬁcant during cumulative follow-up (Manson et al.,
2013). Furthermore, for CEE alone, younger women (aged 50–
59 years) had more favourable results for myocardial infarc-
tion, all-cause mortality and the global index (Manson et al.,
2013). All these ﬁndings clearly demonstrate that MHT is ben-
eﬁcial for women aged around 50–59 years, and especially for
menopausal women who have underone hysterectomies (no
need for a progestagen).
Therefore, the key questions arising in the debate about
MHT and THT for postponing menopause are as follows: is
natural late menopause (>age 55 years), as a model for ex-
tended physiological ovarian activity, beneﬁcial for women’s
health at all? Does THT create a more physiological hor-
monal proﬁle? And, if yes, is THT, therefore, more beneﬁ-
cial than MHT, assuming long-term tissue activity after
transplantation?
Late menopause has been associated with a decreased risk
for coronary artery disease (Barrett-Connor, 2013), whereas
breast cancer risk was increased (Monninkhof et al., 1999).
Accordingly, cardiovascular mortality has been found to be
decreased in women with late menopause (Jacobsen et al.,
2000). Overall mortality, however, has been reported to be
decreased (Jacobsen et al., 2003) or unchanged (Jacobsen
et al., 1999). Therefore, cardiovascular health will be the main
end-point when considering THT for postponing menopause.
Ovaries produce a broad spectrum of oestrogenic,
progestagenic and androgenic hormones that are released in
a deﬁned pulsatile rhythm. It is assumed, but not yet proven,
that transplanted ovarian tissue produces the same pulsa-
tile spectrum of steroid hormones. We do not know, however,
if a more physiological steroid hormone proﬁle is more ben-
eﬁcial than a ﬁxed combination of one or two hormones within
an MHT preparation. Furthermore, we do not know when the
optimal time point for ovarian tissue transplantation would
be, as already slight hormonal changes during the
perimenopause may be associated with symptoms such as hot
ﬂushes, sleep disorders and abnormal uterine bleeding in need
of treatment. It might be that transplanted ovarian tissue with
only a small follicle pool will result in a similar but not better
hormonal proﬁle compared with the natural menopausal tran-
sition warranting additional MHT.
Reproductive aspects
Social freezing to postpone child bearing has also become a
topic of interest. So far, it is limited to cryopreservation of
oocytes. Although social freezing is already widely offered
and carried out, it is still controversial (von Wolff et al.,
2015). For example, social freezing may not solve social
problems but only postpone them. Pregnant women are
potentially becoming older, leading to higher obstetrical
risks. Social freezing usually requires IVF. In mice and
humans, IVF has been found to increase risk of malforma-
tions and functional disorders, such as an increased carotis–
intima–media thickness, leading to an increased pulmonary
blood pressure (von Wolff et al., 2015). The increased risk
of malformation may be attributed to a general predisposi-
tion owing to the infertility itself; however, functional
disorders, which are probably caused by epigenetic modiﬁ-
cations, cannot. Therefore, social freezing using ovarian
tissue followed by IVF is possibly associated with an in-
creased health risk for the offspring.
Pregnancies may also be achieved after transplantation of
ovarian tissue without IVF. Tissue transplanted into the re-
maining ovary and even into a peritoneal pocket can lead to
spontaneous pregnancies (Liebenthron et al., 2015). There-
fore, cryopreservation of ovarian tissue might also be an in-
teresting alternative to social freezing. Data on the technique’s
efﬁcacy and on children’s outcome after having used this tech-
nique are still limited; therefore, cryopreservation of ovarian
tissue to postpone child bearing cannot yet be generally
recommended.
Discussion
As life expectancy increases, women spend about one-third
of their lives after menopause; that is, in a state of oestro-
gen deﬁciency. Considering the predominantly beneﬁcial effect
of late menopause and MHT on women’s health, one might
hypothesize that postponing menopause by transplanting pre-
viously cryopreserved functioning ovarian tissue may have a
beneﬁcial effect on the individual. Some objections have been
made to this hypothesis. First, restoring one organ’s func-
tion does not necessarily imply a beneﬁt for the whole
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‘biosystem’ human being. Second, although steroid
hormones do play a central role in the ageing process, they
cannot compensate for other, internal or external, risk factors
such as genetic predisposition, lifestyle (e.g. smoking and
obesity), social and work-place environment. Next, age at ini-
tiation of steroid hormone exposure has no effect. Although
exogenous oestrogens during peri- and early postmenopause
have a preventive effect on atherosclerosis progression, they
have an opposite effect when initiated at a later age (>60
years) (Hodis and Mack, 2014). Therefore, the effect of THT
on women’s health will also depend on the timing of
transplantation.
Most likely, THT will improve menopausal symptoms, but
still needs to be scientiﬁcally proven. Also, unlike MHT, THT
will not be easily adaptable and might require some addi-
tional MHT for menopausal symptom relief. THT will result
in the production of oestrogen and progesterone, which may
increase breast cancer risk. In women who have undergone
hysterectomies, oestrogen-only therapy would be the pre-
ferred choice of treatment as it reduces breast cancer risk
(Manson et al., 2013). Finally, the duration of tissue activity
can neither be estimated nor can the hormone production be
reduced or stopped without further surgery. To really com-
pensate for MHT, the transplanted tissue should be active for
at least 5 years with continuous follicle growth to avoid phases
with low oestrogen production, which would otherwise cause
menopausal symptoms and could reduce the postulated beneﬁt
for women’s health.
Cost also has a role to play. Accordingly, insurance
companies will only reimburse treatments that are beneﬁ-
cial, effective and economically sound. Conventional MHT is
quite cheap. In contrast, THT requires two laparoscopies,
one for removal of the tissue and one for re-transplantation,
and long-term storage of the tissue. Surgery does not only
set a woman at health risk but is also more expensive than
MHT.
Therefore, THT is an interesting alternative to postpon-
ing menopause (Table 1). From an endocrinological, economic
and safety point of view, it is currently not an alternative to
a MHT if tissue is exclusively cryopreserved and
transplanted for postponing menopause. If instead, THT
was used for both postponing child bearing and menopause
the risk–beneﬁt ratio would shift towards the beneﬁts as
the tissue is not removed and stored exclusively for postpon-
ing menopause. Therefore, if the efﬁcacy of tissue
transplantation to induce pregnancies was further in-
creased, this double strategy could possibly become an
alternative option.
In conclusion, transplanting ovarian tissue to exclusively
postpone menopause is currently doubtful from an endocri-
nological point of view. As transplanted tissue has been shown
to successfully generate spontaneous pregnancies, and as-
suming that the activity of the transplanted tissue can be
further increased, cryopreservation of ovarian tissue to
combine both, social freezing and postponing menopause,
might become a feasible option with an acceptable risk–
beneﬁt ratio in the future.
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